- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07944560
Development of dEep EndometrioSis Following Acute haemoPerITonEum (DEESPITE)
This study investigates whether acute pelvic pain with haemoperitoneum is associated with an increased risk of developing deep pelvic endometriosis, compared with acute pelvic pain without haemoperitoneum. Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to a single follow-up visit, including a transvaginal ultrasound and validated questionnaires.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a single-centre, non-pharmacological, interventional, no-profit study conducted at the Obstetric-Gynecological Emergency Department and the Infertility Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to participate. Cases are women with documented haemoperitoneum and no previous diagnosis of endometriosis. Controls are women with acute pelvic pain without haemoperitoneum and no previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year). Women with previous hysterectomy or oophorectomy, or established menopause, are excluded.
Participants who provide informed consent will attend a single follow-up visit, lasting approximately one hour. The visit includes a second-level transvaginal ultrasound to identify lesions suggestive of deep endometriosis according to the IDEA criteria, and validated questionnaires assessing quality of life (SF-12), endometriosis-specific quality of life (EHP-30), sexual function (FSFI) and pain (NRS).
The primary outcome is the incidence of sonographically diagnosed deep pelvic endometriosis between 6 months and up to 5 years after the acute event, comparing cases and controls. Secondary outcomes include the impact of the acute event on chronic pelvic pain and quality of life, and the association between treatment of the acute event (surgical vs conservative) or use of hormonal therapy during follow-up and the development of endometriosis.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Edgardo Somigliana, PhD
- Numero di telefono: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
Backup dei contatti dello studio
- Nome: Marco Reschini, MSc
- Numero di telefono: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
Luoghi di studio
-
-
MI
-
Milan, MI, Italia, 20122
- Reclutamento
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contatto:
- Edgardo Somigliana, PhD
- Numero di telefono: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
-
Contatto:
- Marco Reschini, MSc
- Numero di telefono: +39 0255034311
- Email: procreazioneassistita@policlinico.mi.it
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024
Descrizione
Inclusion Criteria:
- Women aged 18-50 years
- Female sex
- Attendance at the Obstetric-Gynecological Emergency Department (Clinica Mangiagalli) for acute pelvic pain
- For cases: documented haemoperitoneum without a previous diagnosis of endometriosis
- For controls: no documented haemoperitoneum without a previous diagnosis of endometriosis
Exclusion Criteria:
- Previous hysterectomy and/or oophorectomy
- Established menopause
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Haemoperitoneum
Women aged 18-50 with acute pelvic pain and documented haemoperitoneum, without a previous diagnosis of endometriosis |
|
No haemoperitoneum
Women aged 18-50 with acute pelvic pain and no documented haemoperitoneum, without a previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of sonographically diagnosed deep pelvic endometriosis
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Incidence of deep pelvic endometriosis diagnosed by second-level transvaginal ultrasound according to IDEA criteria, comparing cases (haemoperitoneum) and controls (no haemoperitoneum) |
From 6 months up to 5 years after the acute event
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pelvic pain intensity assessed using the Numeric Rating Scale (NRS)
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Comparison of pelvic pain intensity between participants with and without haemoperitoneum at the index acute event, assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity. |
From 6 months up to 5 years after the acute event
|
|
Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30)
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Comparison of the Endometriosis Health Profile-30 (EHP-30) overall summary score between participants with and without haemoperitoneum at the index acute event. The core questionnaire contains 30 items, each scored from 0 to 4. A single overall score is calculated by summing the scores of all 30 items, dividing the sum by the maximum possible score of 120, and multiplying by 100. The overall score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Quality of life assessed using the Short Form Health Survey (SF-12)
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Comparison of the 12-Item Short Form Health Survey (SF-12) scores between participants with and without haemoperitoneum at the index acute event. Scores will be calculated using the questionnaire's standard scoring algorithm. Norm-based scores have a reference population mean of 50 and a standard deviation of 10, with higher scores indicating better physical health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Sexual function assessed using the Female Sexual Function Index (FSFI)
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Comparison of Female Sexual Function Index (FSFI) total scores between participants with and without haemoperitoneum at the index acute event. The FSFI is a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Weighted domain scores are summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function. |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to initial treatment
Lasso di tempo: From 6 months up to 5 years after the acute event
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants initially managed surgically with those managed conservatively. Initial treatment will be classified from medical records. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to hormonal therapy use
Lasso di tempo: From 6 months up to 5 years after the index acute event.
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants who received hormonal therapy during follow-up with those who did not. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the index acute event.
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Dolore
- Manifestazioni neurologiche
- Processi patologici
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie dell'apparato digerente
- Malattie genitali, femmina
- Emorragia
- Malattie peritoneali
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Endometriosi
- Dolore pelvico
- Emoperitoneo
Altri numeri di identificazione dello studio
- PMA2025_02
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .